title: Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.
abstract: Early detection of ovarian cancer might improve clinical outcome. Some studies have shown the role of cytokines as a new group of tumor markers for ovarian cancer. We hypothesized that a panel comprised of multiple cytokines, which individually may not show strong correlation with the disease, might provide higher diagnostic power. To evaluate the diagnostic utility of cytokine panel, we used a novel multianalyte LabMAP profiling technology that allows simultaneous measurement of multiple markers. Concentrations of 24 cytokines (cytokines/chemokines, growth, and angiogenic factors) in combination with cancer antigen-125 (CA-125), were measured in sera of 44 patients with early-stage ovarian cancer, 45 healthy women, and 37 patients with benign pelvic tumors. Six markers, i.e., interleukin (IL)-6, IL-8, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), and CA-125, showed significant differences in serum concentrations between ovarian cancer and control groups. Out of this group, IL-6, IL-8, VEGF, EGF, and CA-125, were used in a classification tree analysis that resulted in 84% sensitivity at 95% specificity. The receiver operator characteristic curve created using the combination of markers produced sensitivities between 90% and 100% in the area of 80% to 90% specificity, whereas the receiver operator characteristic curve for CA-125 alone resulted in sensitivities of 70% to 80%. The classification tree analysis for discrimination of benign condition from ovarian cancer used CA-125, granulocyte colony-stimulating factor (G-CSF), IL-6, EGF, and VEGF resulting in 86.5% sensitivity and 93.0% specificity. The presented data show that simultaneous testing of a panel of serum cytokines and CA-125 using LabMAP technology may present a promising approach for ovarian cancer detection.
authors.affiliation: Department of Pathology and Immunology, University of Pittsburg School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
authors.forename: Elieser
authors.initials: E
authors.lastname: Gorelik
authors.forename: Douglas P
authors.initials: DP
authors.lastname: Landsittel
authors.forename: Adele M
authors.initials: AM
authors.lastname: Marrangoni
authors.forename: Francesmary
authors.initials: F
authors.lastname: Modugno
authors.forename: Lyudmila
authors.initials: L
authors.lastname: Velikokhatnaya
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Winans
authors.forename: William L
authors.initials: WL
authors.lastname: Bigbee
authors.forename: Ronald B
authors.initials: RB
authors.lastname: Herberman
authors.forename: Anna E
authors.initials: AE
authors.lastname: Lokshin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D011237:Predictive Value of Tests; D012372:ROC Curve
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D016207:Cytokines